（文章来源：每日经济新闻） 每经AI快讯，10月13日，港股巨子生物(02367.HK)跌超5%，截至发稿，跌5.33%，报50.6港元，成交额 6.28亿港元。 ...

消息面上，2025年双十一电商大促已经提前启动。华泰证券此前指出，在25Q2面临一定外部因素影响 的背景下，巨子生物上半年收入与利润仍能双增，且盈利能力维持相对稳定，彰显品牌定力与业绩韧 性。双11旺季临近，公司品牌宣传/达人推广等活动有望逐步恢复并带动公司H2增长提速。 巨子生物(02367)再跌超5%，截至发稿，跌5.33%，报50.6港元，成交额6.28亿港元。 值得注意的是，华熙生物9月底表示，已联合国家计量院等多家第三方检测机构对相关企业的相关产品 展开检测，结果几十份检测结果均显示，相关产品中的重组胶原蛋白添加量未达标。华熙生物表 示，"已将数十份检测报告提交国家药品监督管理局。"分析人士称，可复美在今年618电商大促中失 意，市场将重点关注双11期间可复美电商销售表现。 ...

值得注意的是，华熙生物9月底表示，已联合国家计量院等多家第三方检测机构对相关企业的相关产品 展开检测，结果几十份检测结果均显示，相关产品中的重组胶原蛋白添加量未达标。华熙生物表 示，"已将数十份检测报告提交国家药品监督管理局。"分析人士称，可复美在今年618电商大促中失 意，市场将重点关注双11期间可复美电商销售表现。 智通财经APP获悉，巨子生物(02367)再跌超5%，截至发稿，跌5.33%，报50.6港元，成交额6.28亿港 元。 消息面上，2025年双十一电商大促已经提前启动。华泰证券此前指出，在25Q2面临一定外部因素影响 的背景下，巨子生物上半年收入与利润仍能双增，且盈利能力维持相对稳定，彰显品牌定力与业绩韧 性。双11旺季临近，公司品牌宣传/达人推广等活动有望逐步恢复并带动公司H2增长提速。 ...

Summary of the Conference Call for Juzi Biotechnology Company Overview - Juzi Biotechnology is a pioneer in the research and production of recombinant collagen, focusing on functional skincare products, medical devices, and functional foods. The company has the most comprehensive collagen molecular library globally and has contributed to the establishment of the first industry standards for recombinant collagen in China [3][4]. Industry Insights - The beauty and skincare industry is experiencing a shift towards differentiated competition, with Juzi leveraging its proprietary recombinant collagen technology through brands like Kefu Mei and Keli Jin. Kefu Mei is seeing rapid growth, while Keli Jin has returned to a growth trajectory after adjustments [2][4]. Key Financial Performance - Juzi Biotechnology projects a 25% revenue growth and a 20% profit growth for the year. The company anticipates strong performance in the second half of the year, supported by collaborations with key influencers for promotional events like Double Eleven [4][14]. Online and Offline Channel Strategy - Online sales account for 75% of total revenue, expected to rise above 80%. The company employs a GTC model for online sales, while offline sales are conducted through a distribution model with lower sales costs. Juzi is expanding its product offerings in pharmacies and hospitals, and has launched a new brand, "Ke Yu," targeting family consumption [2][8][9]. Response to Market Challenges - The company has effectively managed short-term public relations challenges by stabilizing gross sales margins and optimizing cost structures. Collaborations with influencers are strategically planned to avoid significant fluctuations in operating margins [6][11]. Pricing Strategy - During the Double Eleven shopping festival, Juzi maintained stable pricing to prevent negative consumer perceptions regarding brand value. The company selectively participated in promotional activities, ensuring minimal impact on gross margins [7][14]. Product Development and Innovation - Juzi is actively tracking market trends and new ingredients, such as PDR, to enhance its product offerings. The company emphasizes scientific validation and consumer value in its product development strategy, avoiding the release of ineffective products [12][13]. Future Outlook - The company is optimistic about its growth trajectory, particularly in the cosmetics and medical aesthetics sectors. Juzi is focused on steady development, with plans to enhance its online presence and maintain a robust offline foundation. The company is also exploring international markets, albeit at a cautious pace [15][16].

公司名稱: 巨子生物控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 ...

Group 1: Financial Performance - The company reported a revenue of 3.11 billion, representing a year-on-year increase of 22.5%, and a net profit attributable to the parent company of 1.18 billion, up 20%, meeting market expectations [1] - Gross margin stood at 81.7%, down 0.7 percentage points, while net profit margin was 38.0%, down 0.6 percentage points [1] - Revenue breakdown shows 82% from the brand "可复美" and 16% from "可丽金", with "可复美" generating 2.54 billion (up 23%) and "可丽金" 503 million (up 27%) [1] Group 2: Strategic Initiatives - The company is expanding production capacity and global presence by adding new production lines for collagen, cosmetics, and medical devices, and constructing new factories for medical devices and health products [2] - A new regional headquarters has been established in Xiamen Free Trade Zone, which will serve as a business settlement center, manufacturing base, and cross-border trade platform [2] - The company is actively participating in major exhibitions and has made significant inroads into markets like Hong Kong and Malaysia, marking a breakthrough in overseas sales [2] Group 3: R&D and Supply Chain Management - The core R&D and management team remains stable, providing a solid foundation for the company's development [2] - The company is focusing on functional skincare and medical devices, with several new products in the R&D or registration phase, expected to launch in the first half of next year [2] - Supply chain management capabilities are being optimized through long-term partnerships with quality raw material suppliers and digital management of production, warehousing, and logistics [2] Group 4: Investment Outlook - The company is positioned as a leader in the application of synthetic biology in the beauty and medical fields, with high technical barriers and increasing brand recognition [3] - Short-term performance is stabilizing, while long-term growth is supported by new product launches and deeper global expansion [3] - Projected net profits for 2025-2027 are 2.502 billion, 3.008 billion, and 3.655 billion, corresponding to PE ratios of 22.0, 18.3, and 15.1, respectively, with a target price of 69.04 HKD for 2025 [3]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - China's rich pool of engineers and scientists, along with efficient and cost-effective clinical trials and drug manufacturing capabilities, are seen as core competitive advantages for pharmaceutical innovation [2] - The impact of the US imposing tariffs on innovative drugs is expected to be limited for the CXO sector, as many multinational pharmaceutical companies already have plans to build factories in the US [2] - Future growth in innovative drugs is anticipated to be driven by overseas partners pushing clinical development for licensed pipelines [2]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - The US is expected to impose tariffs on innovative drugs, but the impact on the CXO sector is anticipated to be limited [2] - Trump's announcement on September 25 states that unless pharmaceutical companies are building factories in the US, patented drugs will face a 100% tariff starting October 1 [2] - The continuous upward momentum for innovative drugs is expected to primarily come from overseas partners pushing clinical developments for authorized pipelines [2]

Core Viewpoint - The MSCI China Healthcare Index has increased by 74.0% year-to-date, outperforming the MSCI China Index by 37.3% [1] Group 1: Market Trends - The recovery in capital market financing and the increase in overseas trading scale for innovative drugs have led to a rebound in domestic innovative drug research and development demand [1] - The CXO industry is expected to see performance recovery in the second half of the year due to the impact of U.S. interest rate cuts [1] Group 2: Regulatory Impact - The anticipated increase in tariffs on innovative drugs by the U.S. is expected to have a limited impact on the CXO sector [1] - Many multinational pharmaceutical companies already have plans to establish factories in the U.S., which may mitigate potential negative effects [1] Group 3: Future Outlook - The ongoing upward momentum for innovative drugs is expected to primarily come from overseas partners driving clinical progress for authorized pipelines [1] - There is optimism regarding valuation recovery opportunities in consumer healthcare, with recommendations to buy stocks in companies such as 3SBio, Junshi Biosciences, WuXi AppTec, Genscript Biotech, China National Pharmaceutical Group, and Innovent Biologics [1]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 69.04 HKD [2][9]. Core Insights - The company is experiencing a recovery in its data, indicating stabilization in its performance. The growth momentum is expected to be strong due to new product launches and global expansion efforts [9]. - The company is a leader in the application of synthetic biology in the beauty and medical fields, with a high technical barrier and increasing brand recognition [9]. - Financial projections indicate significant revenue growth, with total revenue expected to reach 6,907 million HKD in 2025, representing a year-on-year growth of 24.7% [5][10]. Financial Summary - Total revenue projections for the company are as follows: - 2024: 5,539 million HKD - 2025: 6,907 million HKD - 2026: 8,495 million HKD - 2027: 10,312 million HKD - Net profit projections are: - 2024: 2,062 million HKD - 2025: 2,502 million HKD - 2026: 3,008 million HKD - 2027: 3,655 million HKD - Earnings per share (EPS) are projected to increase from 2.01 HKD in 2024 to 3.41 HKD in 2027 [5][10][11]. Market Position and Strategy - The company is expanding its production capacity and global footprint, including establishing a regional headquarters in Xiamen and participating in international trade shows [9]. - The core team remains stable, focusing on continuous product development, particularly in functional skincare and medical devices [9]. - Supply chain management is being optimized to enhance cost control and market responsiveness, ensuring stable growth [9].